Calithera Biosciences, Inc. (NASDAQ:CALA) Short Interest Update

Calithera Biosciences, Inc. (NASDAQ:CALAGet Rating) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 2,540,000 shares, a growth of 32.3% from the March 31st total of 1,920,000 shares. Based on an average daily volume of 2,710,000 shares, the days-to-cover ratio is currently 0.9 days.

A number of research firms have commented on CALA. StockNews.com assumed coverage on shares of Calithera Biosciences in a report on Tuesday, April 26th. They issued a “hold” rating for the company. Zacks Investment Research cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th. LADENBURG THALM/SH SH assumed coverage on shares of Calithera Biosciences in a report on Monday, January 31st. They set a “buy” rating and a $4.00 price objective for the company. Finally, SVB Leerink reduced their price objective on shares of Calithera Biosciences from $3.00 to $2.00 and set an “outperform” rating for the company in a report on Monday, April 4th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $2.63.

Calithera Biosciences stock opened at $0.25 on Tuesday. Calithera Biosciences has a fifty-two week low of $0.23 and a fifty-two week high of $2.59. The stock has a market cap of $18.96 million, a PE ratio of -0.16 and a beta of 1.48. The firm’s 50-day simple moving average is $0.41 and its 200 day simple moving average is $0.71.

Calithera Biosciences (NASDAQ:CALAGet Rating) last announced its quarterly earnings data on Thursday, March 31st. The biotechnology company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04. During the same quarter in the prior year, the business posted ($0.32) earnings per share. On average, equities analysts predict that Calithera Biosciences will post -0.62 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in CALA. Morgan Stanley raised its position in Calithera Biosciences by 288,904.1% in the second quarter. Morgan Stanley now owns 985,504 shares of the biotechnology company’s stock worth $2,060,000 after acquiring an additional 985,163 shares during the period. Bank of America Corp DE raised its position in Calithera Biosciences by 90.4% in the second quarter. Bank of America Corp DE now owns 100,212 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 47,568 shares during the period. Raymond James Financial Services Advisors Inc. bought a new stake in Calithera Biosciences in the third quarter worth about $27,000. Transcend Wealth Collective LLC raised its position in shares of Calithera Biosciences by 50.6% in the third quarter. Transcend Wealth Collective LLC now owns 29,771 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 10,000 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Calithera Biosciences by 16.3% in the third quarter. Geode Capital Management LLC now owns 804,384 shares of the biotechnology company’s stock valued at $1,753,000 after purchasing an additional 112,622 shares during the period. 55.84% of the stock is currently owned by institutional investors and hedge funds.

About Calithera Biosciences (Get Rating)

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology.

Featured Articles

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.